Q2 2024 Earnings Forecast for Gilead Sciences, Inc. (NASDAQ:GILD) Issued By Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Zacks Research reduced their Q2 2024 EPS estimates for Gilead Sciences in a report issued on Tuesday, April 23rd. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will earn $1.40 per share for the quarter, down from their prior estimate of $1.54. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.55 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.12 EPS, Q1 2026 earnings at $1.43 EPS and FY2026 earnings at $7.18 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company posted $1.67 EPS.

A number of other research analysts have also issued reports on GILD. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Cantor Fitzgerald dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. Royal Bank of Canada dropped their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Finally, Barclays dropped their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $84.71.

Gilead Sciences Stock Up 0.1 %

GILD stock opened at $67.03 on Wednesday. The stock has a market capitalization of $83.46 billion, a P/E ratio of 14.90, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences has a 12 month low of $65.90 and a 12 month high of $87.86. The firm has a 50-day moving average price of $71.68 and a 200-day moving average price of $76.46.

Institutional Trading of Gilead Sciences

Hedge funds have recently bought and sold shares of the business. Altfest L J & Co. Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at $210,000. Federated Hermes Inc. grew its position in Gilead Sciences by 4.9% in the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after purchasing an additional 175,925 shares during the period. Wetzel Investment Advisors Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at $74,000. Abundance Wealth Counselors acquired a new stake in Gilead Sciences in the 3rd quarter valued at $1,881,000. Finally, Toronto Dominion Bank boosted its holdings in Gilead Sciences by 66.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock worth $96,589,000 after acquiring an additional 515,191 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.29% of the company’s stock.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.59%. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.